Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients

Summary

assess the activity and toxicity of second-line treatment with pazopanib after failure of first-line sunitinib treatment in patients with clear cell mRCC; to investigate the potential association of DLL4, Notch1, VEGFA, PDGFRB, HIF-1α and HIF-2α with clinical response to pazopanib in mRCC patients.

Timeline

Start

2014-07

Primary completion

2015-12

Completion

2015-12

Drugs

Indications